Clinical Trial Update: A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 pilot study evaluated romidepsin in relapsed or refractory extranodal NK/T-cell lymphoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• Romidepsin (romidepsin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Histologically Proven Extranodal NKTcell Lymphoma | EARLY_Phase 1 | Status: COMPLETED